In this issue:
Omitting axillary dissection in breast cancer with sentinel-node metastases
Ribociclib + endocrine therapy in early breast cancer
Brain RT-pyrotinib-capecitabine in HER2+ advanced breast cancer and brain metastases
Validation of RSClin
Axillary dissection for determining abemaciclib use in hormone receptor+, HER2– breast cancer with 1–2 sentinel nodes
Evaluation of Oncotype Dx in node+, hormone receptor+, HER2– breast cancer
HER2 changes from pretreatment biopsy to residual disease after neoadjuvant therapy for breast cancer
Metronomic vs. weekly first-line vinorelbine in hormone receptor+, HER2– advanced breast cancer
Local therapy only for <5 brain metastases from HER2+ breast cancer
Olaparib ± durvalumab in platinum-pretreated advanced TNBC
Please login below to download this issue (PDF)